Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update

Immunovant, Inc. (NASDAQ:IMVT) ranks among the most shorted stocks to buy according to analysts. On February 6, Immunovant, Inc. (NASDAQ:IMVT) released its Q3 2025 results, reporting a smaller-than-anticipated quarterly loss of -$0.61 per share, surpassing consensus projections of -$0.72 by $0.11.

Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update

The quarter’s net loss of $110.6 million was slightly higher than the $111.1 million for the same period a year earlier. Moreover, while general and administrative costs fell to $15.4 million from $19.8 million year-over-year, the company’s R&D expenditures rose to $98.9 million from $94.5 million.

Immunovant, Inc. (NASDAQ:IMVT) anticipates receiving topline findings in the latter half of 2026 from its proof-of-concept trial in cutaneous lupus erythematosus as well as its IMVT-1402 trial in rheumatoid arthritis. Furthermore, the company expects to release data from its Phase 3 trials of batoclimab for thyroid eye disease in the first half of this year.

Following the results, multiple analysts reiterated their views but raised price targets. Among them was Guggenheim analyst Yatin Suneja, who raised his target from $41 to $44 on February 9. In addition, Truist analyst Danielle Brill also reiterated a Hold rating on the stock but raised the target to $23 from $22.

Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage immunology company focused on developing innovative therapies for autoimmune diseases. The company’s primary focus is on creating anti-FcRn (neonatal Fc receptor) antibodies, which aim to reduce harmful immunoglobulin G (IgG) autoantibodies in patients with various autoimmune conditions.

While we acknowledge the potential of IMVT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IMVT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.